189 related articles for article (PubMed ID: 36835265)
1. Potential of uPAR, αvβ6 Integrin, and Tissue Factor as Targets for Molecular Imaging of Oral Squamous Cell Carcinoma: Evaluation of Nine Targets in Primary Tumors and Metastases by Immunohistochemistry.
Lawaetz M; Christensen A; Juhl K; Karnov K; Lelkaitis G; Kanstrup Fiehn AM; Kjaer A; von Buchwald C
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835265
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [
Lawaetz M; Binderup T; Christensen A; Juhl K; Lelkaitis G; Lykke E; Knudsen L; von Buchwald C; Kjaer A
Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
[TBL] [Abstract][Full Text] [Related]
3. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
4. Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer.
Christensen A; Kiss K; Lelkaitis G; Juhl K; Persson M; Charabi BW; Mortensen J; Forman JL; Sørensen AL; Jensen DH; Kjaer A; von Buchwald C
BMC Cancer; 2017 Aug; 17(1):572. PubMed ID: 28841839
[TBL] [Abstract][Full Text] [Related]
5. Expression patterns of uPAR, TF and EGFR and their potential as targets for molecular imaging in oropharyngeal squamous cell carcinoma.
Christensen A; Grønhøj C; Jensen JS; Lelkaitis G; Kiss K; Juhl K; Charabi BW; Mortensen J; Kjær A; Von Buchwald C
Oncol Rep; 2022 Aug; 48(2):. PubMed ID: 35775375
[TBL] [Abstract][Full Text] [Related]
6. Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.
Ghosh S; Koblinski J; Johnson J; Liu Y; Ericsson A; Davis JW; Shi Z; Ravosa MJ; Crawford S; Frazier S; Stack MS
Mol Cancer Res; 2010 Feb; 8(2):145-58. PubMed ID: 20145038
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis.
Nozaki S; Endo Y; Kawashiri S; Nakagawa K; Yamamoto E; Yonemura Y; Sasaki T
Oral Oncol; 1998 Jan; 34(1):58-62. PubMed ID: 9659521
[TBL] [Abstract][Full Text] [Related]
8. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the interaction between heterodimeric αvβ6 integrin and urokinase plasminogen activator receptor (uPAR) using functional proteomics.
Ahn SB; Mohamedali A; Anand S; Cheruku HR; Birch D; Sowmya G; Cantor D; Ranganathan S; Inglis DW; Frank R; Agrez M; Nice EC; Baker MS
J Proteome Res; 2014 Dec; 13(12):5956-64. PubMed ID: 25318615
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.
Bacchiocchi R; Rubini C; Pierpaoli E; Borghetti G; Procacci P; Nocini PF; Santarelli A; Rocchetti R; Ciavarella D; Lo Muzio L; Fazioli F
BMC Cancer; 2008 Aug; 8():220. PubMed ID: 18673553
[TBL] [Abstract][Full Text] [Related]
12. EGFR and αvβ6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region.
Baart VM; van Duijn C; van Egmond SL; Dijckmeester WA; Jansen JC; Vahrmeijer AL; Sier CFM; Cohen D
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516897
[TBL] [Abstract][Full Text] [Related]
13. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
Wang J; Guo F; Wei H; Dong J; Wu J
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):515-9. PubMed ID: 16356605
[TBL] [Abstract][Full Text] [Related]
14. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Zheng Q; Tang ZY; Xue Q; Shi DR; Song HY; Tang HB
J Cancer Res Clin Oncol; 2000 Nov; 126(11):641-6. PubMed ID: 11079728
[TBL] [Abstract][Full Text] [Related]
15. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
16. Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller HB; Szekeres A; Binder BR; Stockinger H; Leksa V
Mol Biol Cell; 2009 Feb; 20(3):745-56. PubMed ID: 19037107
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma].
Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Horch HH
Mund Kiefer Gesichtschir; 2004 May; 8(3):180-90. PubMed ID: 15138856
[TBL] [Abstract][Full Text] [Related]
18. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Magnussen S; Rikardsen OG; Hadler-Olsen E; Uhlin-Hansen L; Steigen SE; Svineng G
PLoS One; 2014; 9(7):e101895. PubMed ID: 24999729
[TBL] [Abstract][Full Text] [Related]
19. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
20. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
